We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Silk Technology Stabilizes Vaccines and Antibiotics

By LabMedica International staff writers
Posted on 01 Aug 2012
A new silk-based stabilizer could keep some vaccines and antibiotics stable up to temperatures of 60 °C, potentially eliminating the need to keep them refrigerated.

Researchers at Tufts University School of Engineering (Medford, MA, USA) have developed self-standing silk protein biomaterial matrices that essentially wrap up the live bioactive molecules present in antibiotics and vaccines, protecting the essential bioactive elements, and so can greatly extend the shelf life of the medication. More...
Silk is used because it is a protein polymer with a chemistry, structure, and assembly that can generate a unique environment for the stabilization of bioactive molecules, even at temperatures up to 60 °C, over more than 6 months, which could save billions of dollars every year and increase accessibility to third world populations.

To test the silk stabilizers, the researchers stored the measles, mumps, and rubella (MMR) vaccines for six months at the recommended 4 °C, as well as at 25, 37, and 44° C. The encapsulation in the new silk films maintained the potency with minimal loss over time and enhanced stability, even at very high storage temperatures. Similarly, antibiotics entrapped in silk films maintained near optimal activity even at temperatures as high as 60 °C. In addition, the researchers found that these silk films had the added benefit of protecting one antibiotic against the detrimental effects of light exposure. The study was published on July 9, 2012, in the Proceedings of the National Academy of Sciences of the USA (PNAS).

“We have already begun trying to broaden the impact of what we're doing to apply to all vaccines,” said lead author David Kaplan, PhD, of the department of biomedical engineering. “Based on what we've seen with other proteins, peptides, and enzymes, there's no reason to believe that this wouldn't be universal. This could potentially eliminate the need for a cold-chain system, greatly decreasing costs and enabling more widespread availability of these life-saving drugs.”

Vaccines and antibiotics often need to be refrigerated to prevent alteration of their chemical structures; such alteration can result in less potent or ineffective medications. The need for a cold chain has long been a problem for health care providers, aid organizations, scientists, and pharmaceutical companies, especially in settings where electricity is limited, and failures in the chain result in the loss of nearly half of all global vaccines.

Related Links:

Tufts University School of Engineering




Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
HPV Test
Allplex HPV28 Detection
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Pathology

view channel
Image: Agilent’s PD-L1 IHC 22C3 pharmDx has received EU certification as a companion diagnostic to identify PD-L1–positive ovarian, fallopian tube, or primary peritoneal carcinoma patients eligible for KEYTRUDA (Photo courtesy of Agilent)

PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers

Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.